Ratings Median Technologies

Equities

ALMDT

FR0011049824

Real-time Euronext Paris Other stock markets 04:47:41 2024-05-03 EDT			5-day change	1st Jan Change
2.75 ^EUR	+1.85%		-17.66%	-42.11%

04-29	Median Technologies SA Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	European Investment Bank OKs Median Technologies' Draw Down of Final EUR8.5 Million Loan Tranche	MT

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Over the past four months, analysts' average price target has been revised upwards significantly.
Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
One of the major weak points of the company is its financial situation.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
For the past year, analysts have significantly revised downwards their profit estimates.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Advanced Medical Equipment & Technology

	1st Jan change	Capi.	ESG Refinitiv
MEDIAN TECHNOLOGIES	-42.11%	53.08M	-
THERMO FISHER SCIENTIFIC	+7.62%	218B	B
DANAHER CORPORATION	+6.70%	183B	B-
INTUITIVE SURGICAL, INC.	+11.94%	134B	B-
BOSTON SCIENTIFIC CORPORATION	+24.60%	106B	A-
SIEMENS HEALTHINEERS AG	-1.94%	61.12B	A-
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+4.81%	50.89B	B+
EDWARDS LIFESCIENCES CORPORATION	+11.55%	51.26B	B+
AGILENT TECHNOLOGIES, INC.	-1.09%	40.3B	A
RESMED, INC.	+26.82%	32.05B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes